COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration
Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.
New nursing home guidelines by CMS now require COVID-19 testing for nursing home staff in states with infection rates of 5% or more.
While the antigen test initiative of HHS will play a role in reducing the spread of COVID-19 among vulnerable populations and surrounding communities, mass rapid point of care testing will have implications for clinical laboratories.
While feces are not thought to transmit SARS-CoV-2, there are genetic materials found in the feces of infected individuals, that can be detected by PCR testing.
Screening asymptomatic people regardless of known or unknown COVID-19 exposure is useful, but it will be important to ensure that this testing is used appropriately and that contingency plans are in place to modify operations based on test results.
New research casts doubt on the evidence that SARS-CoV-2 serology testing yields useful data.
With serological assays for SARS-CoV-2 widely available, uncertainty remains around the accuracy of these tests. The revocation of Chembio’s SARS-CoV-2 serology EUA could indicate broader and stricter enforcement by the FDA.
New nursing home guidelines by CMS now require COVID-19 testing for nursing home staff in states with infection rates of 5% or more.
While the antigen test initiative of HHS will play a role in reducing the spread of COVID-19 among vulnerable populations and surrounding communities, mass rapid point of care testing will have implications for clinical laboratories.
While feces are not thought to transmit SARS-CoV-2, there are genetic materials found in the feces of infected individuals, that can be detected by PCR testing.
Screening asymptomatic people regardless of known or unknown COVID-19 exposure is useful, but it will be important to ensure that this testing is used appropriately and that contingency plans are in place to modify operations based on test results.
New research casts doubt on the evidence that SARS-CoV-2 serology testing yields useful data.
With serological assays for SARS-CoV-2 widely available, uncertainty remains around the accuracy of these tests. The revocation of Chembio’s SARS-CoV-2 serology EUA could indicate broader and stricter enforcement by the FDA.
